0000910267 false 0000910267 2021-11-08 2021-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 8, 2021

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-13341 | 94-3171940
(Commission File Number) | (IRS Employer Identification No.)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

(Address of principal executive offices and zip code)

650-244-4990

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.001 par value | TTNP | Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| ¨ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure

On November 8, 2021, Titan Pharmaceuticals, Inc. (the “Company”) announced that additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist (“TP-2021”) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model had been reported in a presentation given earlier in the day at the Society for Neuroscience 2021 Meeting.

A copy of the slide presentation, which will be posted on the Company’s website, is attached hereto as Exhibit 99.1 and incorporated herein by reference. The presentation is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 8.01. Other Events.

On November 8, 2021, the Company announced the presentation of data from an ongoing in vivo study of its TP-2021 ProNeura®-based implant. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is filed herewith:

Exhibit Number | Description
99.1 | Presentation at the Society of Neuroscience
99.2 | Press release
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 9, 2021 | TITAN PHARMACEUTICALS, INC.
| By: | /s/ Kate Beebe DeVarney, Ph.D.
| Name: | Kate Beebe DeVarney, Ph.D.
| Title: | President and Chief Operating Officer

3